ENHANCED LONG-TERM CARE OF SEVERE RESPIRATORY FAILURE

描述：(改编自《调查员摘要》)现任管理层 严重急性呼吸衰竭中危及生命的低氧血症/高碳酸血症 (ARF)是次优的。动静脉二氧化碳清除术(AVCO2R) 结合温和的通风来引入氧气已经显示出希望。 AVCO2R是一种温和的无泵技术，利用现有的低压降膜 劳动强度更低、成本更低、复杂程度更低、成本更低的氧合器 对病人来说很有压力。虽然AVCO2R在短期内表现出了希望， ARF治疗需要能够连续运行数周的系统。这个 该计划的长期目标是开发一个长期的AVCO2R系统。在……里面 本项目一期工程将对现有的AVCO2R膜式氧合器进行改造 将长期能力从几个小时提高到两周以上。 第一阶段的活动将包括演示这些技术将保持 初始绩效，同时提高长期绩效和增强 生物兼容性。第二阶段将优化性能，执行详细的 进行生物兼容性测试，并进行动物研究。 建议的商业应用：不可用

DESCRIPTION: (Adapted from the Investigator's Abstract) The current management of life-threatening hypoxemia/hypercarbia in severe acute respiratory failure (ARF) is suboptimal. Arteriovenous carbon dioxide removal (AVCO2R) in combination with mild ventilation for introduction of oxygen has shown promise. AVCO2R is a mild pumpless technique using existing low pressure drop membrane oxygenators which is less labor intensive, less costly, less complex, and less stressful to the patient. While AVCO2R has shown promise for short duration, ARF therapy requires systems that can operate continuously for weeks. The long-term objective of this program is to develop a long-term AVCO2R system. In Phase I of this program existing AVCO2R membrane oxygenators will be modified to enhance long-term capability from a few hours to in excess of two weeks. Phase I activity will include demonstration that these techniques will maintain initial performance while improving long-term performance and enhancing biocompatibility. Phase II will optimize performance, perform detailed biocompatibility tests, and carry out animal studies. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE